DK0928291T3 - 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase - Google Patents

3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase

Info

Publication number
DK0928291T3
DK0928291T3 DK97935308T DK97935308T DK0928291T3 DK 0928291 T3 DK0928291 T3 DK 0928291T3 DK 97935308 T DK97935308 T DK 97935308T DK 97935308 T DK97935308 T DK 97935308T DK 0928291 T3 DK0928291 T3 DK 0928291T3
Authority
DK
Denmark
Prior art keywords
mercaptoacetylamino
oxo
inhibitors
substituted
matrix metalloproteinase
Prior art date
Application number
DK97935308T
Other languages
English (en)
Inventor
Alan M Warshawsky
Gary A Flynn
Meena V Patel
Douglas W Beight
Joseph P Burkhart
Jiu-Tsair Tsay
Michael J Janusz
Jian Shen
Ramalinga M Dharanipragada
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK0928291T3 publication Critical patent/DK0928291T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97935308T 1996-09-19 1997-08-04 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase DK0928291T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19
PCT/US1997/013738 WO1998012211A1 (en) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Publications (1)

Publication Number Publication Date
DK0928291T3 true DK0928291T3 (da) 2003-03-17

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97935308T DK0928291T3 (da) 1996-09-19 1997-08-04 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase

Country Status (20)

Country Link
EP (1) EP0928291B1 (da)
JP (1) JP3962091B2 (da)
KR (1) KR100545460B1 (da)
CN (1) CN1150205C (da)
AR (1) AR009363A1 (da)
AT (1) ATE229034T1 (da)
AU (1) AU718055B2 (da)
BR (1) BR9713207A (da)
CA (1) CA2266759C (da)
DE (1) DE69717647T2 (da)
DK (1) DK0928291T3 (da)
ES (1) ES2184126T3 (da)
HU (1) HUP9904165A3 (da)
IL (2) IL129035A0 (da)
NO (1) NO991316L (da)
NZ (1) NZ334490A (da)
PT (1) PT928291E (da)
TW (1) TW445262B (da)
WO (1) WO1998012211A1 (da)
ZA (1) ZA978307B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
CA2356969A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
IN201947051091A (da) 2017-05-31 2019-12-20 B.R.A.I.N. Biotechnology Research And Information Network Ag

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3889726T2 (de) * 1987-03-17 1994-10-13 Res Corp Technologies Inc Synthetische inhibitoren von säugetier-collagenase.
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
NO991316D0 (no) 1999-03-18
TW445262B (en) 2001-07-11
WO1998012211A1 (en) 1998-03-26
HUP9904165A3 (en) 2002-01-28
EP0928291B1 (en) 2002-12-04
HUP9904165A2 (hu) 2000-03-28
NZ334490A (en) 2000-08-25
EP0928291A1 (en) 1999-07-14
NO991316L (no) 1999-05-18
JP2001501926A (ja) 2001-02-13
KR100545460B1 (ko) 2006-01-24
BR9713207A (pt) 2000-04-04
KR20000036246A (ko) 2000-06-26
CA2266759A1 (en) 1998-03-26
AU3827897A (en) 1998-04-14
ATE229034T1 (de) 2002-12-15
HK1020741A1 (en) 2000-05-19
ZA978307B (en) 1998-03-19
PT928291E (pt) 2003-03-31
CA2266759C (en) 2004-10-26
DE69717647D1 (de) 2003-01-16
IL129035A0 (en) 2000-02-17
AR009363A1 (es) 2000-04-12
CN1234039A (zh) 1999-11-03
CN1150205C (zh) 2004-05-19
IL129035A (en) 2006-12-10
DE69717647T2 (de) 2003-09-25
AU718055B2 (en) 2000-04-06
ES2184126T3 (es) 2003-04-01
JP3962091B2 (ja) 2007-08-22

Similar Documents

Publication Publication Date Title
DK0946512T3 (da) 6-Phenylpyridyl-2-aminderivater, der er nyttige som NOS-inhibitorer
DK1165516T3 (da) Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
NO960393D0 (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
DK1100797T3 (da) Heterocycliske forbindelser som inhibitorer af rotamaseenzymer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK0923585T3 (da) Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
NO20022649L (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
DK1060178T3 (da) Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
DK1288206T3 (da) Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
DE69900356D1 (de) Nitro-Isoharnstoffderivate
DK0996622T3 (da) Hidtil ukendte spiroazabicycliske, heterocykliske forbindelser
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
DK1104420T3 (da) Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
DK0912537T3 (da) Fremgangsmåde til fremstilling af phenylheterocykliske forbindelser, der er anvendelige som cox-2-inhibitorer
NO20013675D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer
NO20021407D0 (no) Bifenylderivater anvendt som NHE-3-inhibitorer
NO991316D0 (no) 3-mercaptoacetylamino-1,5-substituerte-2-okso-azepanderivater som er anvendbare som inhibitorer av matriksmetalloproteinase
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1210326T3 (da) Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
NO991994D0 (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriks-metalloproteaseinhibitorer
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase